Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Despite layoffs, Abbott Labs Faces Retirement Wave in 5 Years
- A report in Kiplinger's notes that roughly 25 percent of the employees of Abbott Labs are age 50 or older, and in five years that number could top more than 40 percent. The demographics are likely similar at many other large drug companies. Abbott is experimenting...
- Blog posts 2008-12-01
- Abbott Offers to Study Inuit Lung Disease for Free -- Locals Say No
- Abbott Labs has learned that no good deed goes unpunished, particularly in the frozen north of Canada. The company offered to study a prevalent lung disease in babies in the Nunavut region, free of charge, but the local governmet has turned the company down, according to the Nunutsiaq News. (One...
- Blog posts 2008-12-12
- Abbott Labs Fires Agency That Screwed Up Humira Ads
- Abbott Labs has put its $70 million Humira ad account in review. The review follows a warning letter from the FDA about Humira's advertising, which the government called "misleading." The incumbent agency on the business is Harrison & Star, according to Adweek. The shop has had Humira since 2005, per...
- Blog posts 2009-03-05
- Abbott CEO White Takes a Pay Cut
- Abbott Labs CEO Miles White took a pay cut last year. His total compensation was only $28.3 million, down from $33.3 million the year before, per a proxy filing at the SEC. The cut came despite the judgment by Abbott's board that White "exceeded" his strategic and...
- Blog posts 2009-03-18
- Abbott Labs Q1: Has the Company Taken Its Eye Off the Sales Force Ball?
- Abbott Labs' stock took a beating today even though it posted a 53 percent gain in net income, to $1.4 billion. Investors didn't like that $1 billion of that profit came from a one-off item reflecting the end of a joint venture with TAP. Revenues were flat at $6.7 billion....
- Blog posts 2009-04-15
- Abbott Claims DOJ Let 12 Years' of Drug Pricing Documents Get Destroyed
- Abbott Labs has accused the Department of Justice of failing to preserve 12 years' worth of evidence in a massive case about whether drug companies artificially inflated the price of drugs. by Jim Edwards
- Blog posts 2009-06-09
- Why J&J's $1.7B Win in Abbott Humira Case May be Garbage
- Abbott Labs' management is probably not worrying too much about the $1.7 billion damages award made in favor of Johnson & Johnson's Centocor unit for Humira's infringment on the latter's Remicade patents. That's because the court that awarded the damages is a famous judicial hellhole known for favoring plaintiffs. by...
- Blog posts 2009-06-30
- Abbott Developing Painkiller Spray for Dogs
- Abbott Labs is developing a painkiller spray for pet dogs, the company said. In a partnership with Velcera, Abbott is in clinical trials to bring Promist to market. by Jim Edwards
- Blog posts 2009-08-21
Additional Resources
- Abbott Labs' Secret Weapon: Layoffs
- Sometimes a company does everything right and no one notices: Abbott Labs just unveiled a stellar third quarter and investors shrugged, leaving its stock flat. The basics you already know: Profit up 51 percent to $1.08 billion, sales up 17.6 percent to $7.5 billion. But check out...
- Blog posts 2008-10-15
- Recommending approval for Abbott Labs: ABT, CURE, EQTD, CIEN, STTC.
- M2 PRESSWIRE-28 June 2005-InvestSource Inc.: Recommending approval for Abbott Labs: ABT, CURE, EQTD, CIEN, STTCC1994-2005 M2 COMMUNICATIONS LTD RDATE:28062005 Stocks in the news: Abbott Labs (NYSE: ABT), Curative Health (NASDAQ: CURE), Company Equal Incorporated (OTB: EQTD), Ciena Corporation (NASDAQ: CIEN),...
- Research articles 2005-06-28
- Earnings Preview: Abbott Labs
- Abbott Labs ABT is expected to report Q2 earnings Wednesday, July 15 before market open, with a conference call scheduled for 9:00 am ET. Guidance Analysts are looking for EPS of 89c on revenue of $7.55B. The consensus range is 87c-90c for EPS, and $7.31B-$7.85B for revenue, according to...
- External links 2009-07-14
- Abbott Labs Wins Approval for Drug Eluting Stent
- ChinaBio Today submits: Abbott Labs (NYSE: ABT) was given SFDA approval for its Xience V drug eluting stent system as a treatment for coronary artery disease (CAD), the leading cause of death in China. The approval was based on two worldwide clinical trials that enrolled 1302 patients, including 60...
- External links 2009-09-15
- For The Record.(Briefs)(RadioShack will close 18 of its 156 company-owned stores in the Chicago, CEO Jeffrey Leiden of Abbott Labs resigns.)
- RadioShack will close 18 of its 156 company-owned stores in the Chicago area as part of a previously announced restructuring effort. Stores closing in Chicago are at 1730 W. Fullerton and 1600 W. 13th. Abbott Labs said Jeffrey Leiden, 50, is steppi RadioShack will...
- Research articles 2006-03-27
- Zacks.com Announces That Kelley Wright Highlights the Following Stocks: Abbott Labs and The Limited
- CHICAGO -- Kelley Wright, editor of the Investment Quality Trends newsletter, says short rates will eventually move lower again. Read about Abbott Labs (NYSE:ABT) and The Limited (NYSE:LTD). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Highlights from the October 17 Featured Expert column by Kelley Wright...
- Research articles 2005-10-20
- Zacks Analyst Interview Highlights: Abbott Labs and ViroPharma
- CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Jason Napodano, who discusses Abbott Labs (NYSE: ABT) and ViroPharma (Nasdaq: VPHM). A synopsis of today's Analyst Interview is presented below. The full article can be read at http://at.zacks.com/?id=2678. If you were to give...
- Research articles 2007-01-30
- Earnings Preview: Abbott Labs
- Abbott Labs ABT is expected to report Q3 earnings before market open Wednesday Oct. 15, with a conference call scheduled for 9:00 am ET. Guidance Analysts are looking for a profit of 77c on revenue of $7.35B. The consensus range is 76c to 78c for EPS, and revenue of $7.19B...
- External links 2008-10-14
- Abbott Labs Beefs Up Its Drug Portfolio and Stent Business
- Mike Huckman submits: The market cap of Dow component Johnson & Johnson JNJ is a whopping $200 billion. Abbott Labs ABT is valued at less than half that. But think of Abbott as a kind of mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a...
- External links 2008-08-14
- Earnings Preview: Abbott Labs
- Abbott Labs ABT is expected to report Q4 earnings on Wednesday, January 21 with a conference call scheduled for 9:00 am ET. Guidance Analysts are looking for a profit of $1.06 on revenue of $8B. The consensus range is $1.04-$1.08 for EPS, and revenue of $7.8B-$8.24B, according to First Call....
- External links 2009-01-20
- Abbott Labs: Perfect Stock for Trying Times?
- Paul Price submits: Abbott Labs (NYSE:ABT) April 12, 2009 $44.03 52-week range: $42.62 (April 7, 2009) - $60.78 (Sep. 29, 2008) Dividend: $0.40 quarterly = 3.63% current yield Abbott consists of four major divisions- Pharmaceuticals, Nutritional Products, Diagnostic Products and Vascular treatment products. ABT has an enviable record of earnings...
- External links 2009-04-13
- Zacks.com Announces That the Following Companies Will Release Earnings This Week: Abbott Labs, Apple Computer, First Data, GE and Harley-Davidson
- CHICAGO -- Zacks.com releases its exclusive Weekly Earnings and Sector Update written by Nick Raich, Director of Research. In addition, the following companies will report earnings this week: Abbott Labs (NYSE:ABT), Apple Computer (NASDAQ:AAPL), First Data Corporation (NYSE:FDC), General Electric (NYSE:GE) and Harley-Davidson (NYSE:HDI). To see this week's full report...
- Research articles 2005-07-12
- << Previous
- page 1 of 1
- Next >>
